Barclays lowered the firm’s price target on Clorox (CLX) to $112 from $118 and keeps an Underweight rating on the shares. The firm adjusted models to reflect “muted and decelerating” growth in parts of the personal care space since the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox’s Financial Challenges and Operational Disruptions Lead to Hold Rating
- Clorox price target raised to $135 from $133 at JPMorgan
- Clorox Faces Challenges with ERP Implementation and Competitive Pressures, Leading to Hold Rating
- Clorox Faces Operational Challenges and Market Share Concerns Amid ERP Transition, Earning a Hold Rating
- Clorox’s Modest Growth Outlook Amidst Challenges and Strategic Focus